5‐HT radioligands for human brain imaging with PET and SPECT
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The serotonergic system plays a key modulatory role in the brain and is the target for many drug treatments for brain disorders either through reuptake blockade or via interactions at the 14 subtypes of 5‐HT receptors. This review provides the history and current status of radioligands used for positron emission tomography (PET) and single photon emission computerized tomography (SPECT) imaging of human brain serotonin (5‐HT) receptors, the 5‐HT transporter (SERT), and 5‐HT synthesis rate. Currently available radioligands for in vivo brain imaging of the 5‐HT system in humans include antagonists for the 5‐HT 1A, 5‐HT 1B, 5‐HT 2A, and 5‐HT 4 receptors, and for SERT. Here we describe the evolution of these radioligands, along with the attempts made to develop radioligands for additional serotonergic targets. We describe the properties needed for a radioligand to become successful and the main caveats. The success of a PET or SPECT radioligand can ultimately be assessed by its frequency of use, its utility in humans, and the number of research sites using it relative to its invention date, and so these aspects are also covered. In conclusion, the development of PET and SPECT radioligands to image serotonergic targets is of high interest, and successful evaluation in humans is leading to invaluable insight into normal and abnormal brain function, emphasizing the need for continued development of both SPECT and PET radioligands for human brain imaging. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Molecular biology of 5-HT receptors
Hannon, J., & Hoyer, D. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.03.020 · Cited by 815
Targeting the murine serotonin transporter: insights into human neurobiology
Murphy, D. L., & Lesch, K.-P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2284 · Cited by 478
Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors
Pazos, A., Probst, A., & Palacios, J. M. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90327-7 · Cited by 355
Houle, S., Ginovart, N., Hussey, D., Meyer, J. H., & Wilson, A. A. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000365 · Cited by 276 · cited 1×
“PET studies of [(11)C]DASB in humans showed that the uptake distribution matched that expected for SERT and binding kinetics could be quantified with reference tissue models.(367,372) It was quickly realized that [(11)C]DASB was a superior PET ligand to [(11)C](1)McN5652, both in baboons(373) and in humans(354) but al…”
Ford, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261 · cited 1×
“Growth in the availability of selective ligands for the 5-HT3 receptor came about once the anti-emetic properties of 5-HT3 receptor antagonists were established and is still of interest as an emerging targets in irritable bowel syndrome and alcohol abuse.(275,276) Several selective agonists and antagonists are availab…”
BackgroundGarcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P. L.-H., Francis, P. T., Lasheras, B., & Ramirez, M. J. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.06.007 · Cited by 244
Frokjaer, V. G., Mortensen, E. L., Nielsen, F. Å., Haugbol, S., Pinborg, L. H., Adams, K. H., Svarer, C., Hasselbalch, S. G., Holm, S., Paulson, O. B., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.009 · Cited by 242 · cited 1×
“Following the positive validation studies, [(18)F]altanserin was used to determine changes in 5-HT2A receptor density in relation to aging, 216–219 depression,(220,221) anorexia nervosa/ bulimia,(222,223) obsessive–compulsive disorder,(224) cognitive decline,(225,226) Tourette’s syndrome,(227) risk or onset of schizop…”
Self-citationPerani, D., Garibotto, V., Gorini, A., Moresco, R. M., Henin, M., Panzacchi, A., Matarrese, M., Carpinelli, A., Bellodi, L., & Fazio, F. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.04.233 · Cited by 219
Cannon, D. M., Ichise, M., Fromm, S. J., Nugent, A. C., Rollis, D., Gandhi, S. K., Klaver, J. M., Charney, D. S., Manji, H. K., & Drevets, W. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.005 · Cited by 197
MICHELSEN, K., PRICKAERTS, J., & STEINBUSCH, H. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00912-6 · Cited by 196
Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa
Bailer, U. F., Frank, G. K., Henry, S. E., Price, J. C., Meltzer, C. C., Mathis, C. A., Wagner, A., Thornton, L., Hoge, J., Ziolko, S. K., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.018 · Cited by 161
Adams, K. H., Hansen, E. S., Pinborg, L. H., Hasselbalch, S. G., Svarer, C., Holm, S., Bolwig, T. G., & Knudsen, G. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005055 · Cited by 147
Self-citationGrailhe, R., Grabtree, G. W., & Hen, R. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00933-5 · Cited by 130 · cited 1×
“Only mRNA for the 5-ht5b receptor has so far been found in humans and it is thought that no functional protein is produced due to stop codons.(299,300) There are no available radioligands for either of the 5-ht5 receptors.”
BackgroundEttrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., Lehel, S., Herth, M. M., Madsen, J., Kristensen, J., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1686-8 · Cited by 128
Self-citationA dose-finding study of duloxetine based on serotonin transporter occupancy
Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., Tanada, S., & Suhara, T. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0304-0 · Cited by 110
Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings
Versijpt, J., Van Laere, K. J., Dumont, F., Decoo, D., Vandecapelle, M., Santens, P., Goethals, I., Audenaert, K., Slegers, G., Dierckx, R. A., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00137-9 · Cited by 102
Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0486-0 · Cited by 77
Klein, N., Sacher, J., Geiss-Granadia, T., Mossaheb, N., Attarbaschi, T., Lanzenberger, R., Spindelegger, C., Holik, A., Asenbaum, S., Dudczak, R., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0666-y · Cited by 62
Chalon, S., Tarkiainen, J., Garreau, L., Hall, H., Emond, P., Vercouillie, J., Farde, L., Dasse, P., Varnas, K., Besnard, J.-C., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.042226 · Cited by 56
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram
Lundberg, J., Christophersen, J. S., Petersen, K. B., Loft, H., Halldin, C., & Farde, L. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007486 · Cited by 55
Lundgren, J. D., Newberg, A. B., Allison, K. C., Wintering, N. A., Ploessl, K., & Stunkard, A. J. (2008) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2007.07.006 · Cited by 55
Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET
Ettrup, A., Palner, M., Gillings, N., Santini, M. A., Hansen, M., Kornum, B. R., Rasmussen, L. K., Någren, K., Madsen, J., Begtrup, M., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.074021 · Cited by 50
Self-citationZea-Ponce, Y., Kegeles, L. S., Guo, N., Raskin, L., Bakthavachalam, V., & Laruelle, M. (2002) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00306-2 · Cited by 14
Cited by
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“PET imaging work utilising potent 5-HT releasers and receptor-selective ligands sensitive to this release (Paterson et al., 2010, 2013; Tyacke and Nutt, 2015) may be able to shed new light on the association between enhanced 5-HT transmission and positive mood (Jorgensen et al., 2016) that may help…”
BackgroundMethodSelf-citationA High-Resolution In Vivo Atlas of the Human Brain's Serotonin System
Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., Svarer, C., Greve, D. N., & Knudsen, G. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2830-16.2016 · Cited by 368
“Up to now, specific and validated PET radioligands for use in humans have been developed for the receptors 5-HT1AR, 5-HT1BR, 5-HT2AR, and 5-HT4R and for 5-HTT (Paterson and Kornum, 2013).”
BackgroundSelf-citationRadiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Căinap, C., & Chiș, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 337
Andrews, P. W., Bharwani, A., Lee, K. R., Fox, M., & Thomson, J. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.018 · Cited by 281
“…165 18.3 – 10.7 785 These techniques can measure dynamic changes in neurotransmission induced by pharmacological or physiological challenges if radiotracers measuring monoamine receptor or transporter density are sensitive to changes in endogenous monoamine levels (Paterson et al., 2010, 2013).”
InfluentialBarnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Metadata
- Authors
- Paterson, L. M., Kornum, B. R., Nutt, D. J., Pike, V. W., & Knudsen, G. M.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2011-06-14
- Volume
- 33
- Issue
- 1
- Pages
- 54-111
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W1526312511
- Cited by
- 151
- References
- 24
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.